DoW Toxic Exposures Clinical Trial Award

<p><strong>Summary:</strong> The fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Clinical Trial Award (CTA) mechanism supports the advancement, execution, and analysis of clinical trials with the potential to have a significant impact on the prevention, treatment, or management of symptoms, diseases or conditions associated with or resulting from military-related toxic exposures. Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) designed to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials (including pragmatic clinical trials) to determine efficacy in relevant patient populations.<strong><em>&nbsp;</em></strong></p>

<p><br></p>

<p><strong>Distinctive Features: </strong>To encourage applications that include meaningful and productive collaborations, the FY26 TERP CTA includes a <strong>Partnering Principal Investigator Option (PPIO)</strong>. One Principal Investigator (PI) is identified as the initiating PI, and an additional PI may be identified as a Partnering PI. If recommended for funding, each PI will be named on separate awards. The intent is to support interdisciplinary partnerships, such as those between clinicians and research scientists, that will accelerate the movement of promising interventions/​knowledge products into clinical applications. Partnering should significantly advance the research beyond what would be possible through independent efforts.</p>

<p><br></p>

<p><a href="https://cdmrp.health.mil/pubs/press/2026/terppreann" target="_blank">https://cdmrp.health.mil/pubs/press/2026/terppreann</a></p>